These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
379 related articles for article (PubMed ID: 35768052)
1. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Perales MA; Anderson LD; Jain T; Kenderian SS; Oluwole OO; Shah GL; Svoboda J; Hamadani M Transplant Cell Ther; 2022 Sep; 28(9):546-559. PubMed ID: 35768052 [TBL] [Abstract][Full Text] [Related]
2. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel as Second-line or Later Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Choe JH; Abdel-Azim H; Padula WV; Abou-El-Enein M JAMA Netw Open; 2022 Dec; 5(12):e2245956. PubMed ID: 36520440 [TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma. Nath K; Wudhikarn K; Alarcon Tomas A; Perales MA Expert Opin Drug Saf; 2023 Jan; 22(1):5-15. PubMed ID: 36737060 [TBL] [Abstract][Full Text] [Related]
5. Emerging Role of Autologous CD19 CAR T-Cell Therapies in the Second-Line Setting for Large B-cell Lymphoma: A Game Changer? Mohty R; Moustafa MA; Aljurf M; Murthy H; Kharfan-Dabaja MA Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):73-80. PubMed ID: 36395495 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745 [TBL] [Abstract][Full Text] [Related]
8. Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma. Lionel AC; Westin J Curr Oncol Rep; 2023 Nov; 25(11):1387-1396. PubMed ID: 37861914 [TBL] [Abstract][Full Text] [Related]
9. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. Halford Z; Anderson MK; Bennett LL Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673 [TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature. Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891 [TBL] [Abstract][Full Text] [Related]
11. Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Practical Implications for the Community Oncologist. Jacobson CA; Farooq U; Ghobadi A Oncologist; 2020 Jan; 25(1):e138-e146. PubMed ID: 31585984 [TBL] [Abstract][Full Text] [Related]
12. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Chow VA; Shadman M; Gopal AK Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976 [TBL] [Abstract][Full Text] [Related]
13. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Sehgal A; Hoda D; Riedell PA; Ghosh N; Hamadani M; Hildebrandt GC; Godwin JE; Reagan PM; Wagner-Johnston N; Essell J; Nath R; Solomon SR; Champion R; Licitra E; Fanning S; Gupta N; Dubowy R; D'Andrea A; Wang L; Ogasawara K; Thorpe J; Gordon LI Lancet Oncol; 2022 Aug; 23(8):1066-1077. PubMed ID: 35839786 [TBL] [Abstract][Full Text] [Related]
14. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma. St-Pierre F; Gordon LI Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471 [TBL] [Abstract][Full Text] [Related]
15. Impact of Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572 [TBL] [Abstract][Full Text] [Related]
16. Understanding the differences in outcome between CART studies as second-line treatment in aggressive lymphoma. Dada R J Oncol Pharm Pract; 2023 Jan; 29(1):183-190. PubMed ID: 35786102 [TBL] [Abstract][Full Text] [Related]
17. Development and Use of the Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Axicabtagene Ciloleucel in Large B-Cell Lymphoma: A Review. Locke FL; Go WY; Neelapu SS JAMA Oncol; 2020 Feb; 6(2):281-290. PubMed ID: 31697310 [TBL] [Abstract][Full Text] [Related]
18. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Riedell PA; Hwang WT; Nastoupil LJ; Pennisi M; McGuirk JP; Maziarz RT; Bachanova V; Oluwole OO; Brower J; Flores OA; Ahmed N; Schachter L; Bharucha K; Dholaria BR; Schuster SJ; Perales MA; Bishop MR; Porter DL Transplant Cell Ther; 2022 Oct; 28(10):669-676. PubMed ID: 35850429 [TBL] [Abstract][Full Text] [Related]
19. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Jain T; Bar M; Kansagra AJ; Chong EA; Hashmi SK; Neelapu SS; Byrne M; Jacoby E; Lazaryan A; Jacobson CA; Ansell SM; Awan FT; Burns L; Bachanova V; Bollard CM; Carpenter PA; DiPersio JF; Hamadani M; Heslop HE; Hill JA; Komanduri KV; Kovitz CA; Lazarus HM; Serrette JM; Mohty M; Miklos D; Nagler A; Pavletic SZ; Savani BN; Schuster SJ; Kharfan-Dabaja MA; Perales MA; Lin Y Biol Blood Marrow Transplant; 2019 Dec; 25(12):2305-2321. PubMed ID: 31446199 [TBL] [Abstract][Full Text] [Related]
20. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. Abramson JS Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]